On 4 June 2026, Sino Biopharmaceutical Limited (abbreviated as Sino Biopharm or SBP Group) reported the formal cancellation of 40.35 million previously repurchased ordinary shares.

Prior to the cancellation, the company had 18.75 billion issued shares outstanding. Following the reduction, the share count fell to 18.71 billion, marking a 0.22% contraction in issued capital.

The cancelled shares were repurchased between 21 April and 22 May 2026 at a volume-weighted average price of HKD 5.471 per share. Based on this price, the aggregate consideration for the repurchased shares amounts to approximately HKD 220.75 million.

No treasury shares remain on the balance sheet, and there are no additional redeemed or repurchased shares pending cancellation as of the reporting date.